Answers are grounded in this paper and cite their sources.
Commentary highlights regional differences in metabolic dysfunction-associated steatotic liver disease in India, suggesting targeted prevention strategies.
Metabolic dysfunction-associated steatotic liver disease (MASLD) in India demonstrates marked regional variation influenced by metabolic risk, lifestyle transition, and population-specific susceptibility. This commentary highlights the growing burden of lean MASLD, the importance of visceral adiposity and cardiometabolic dysfunction, and population-specific genetic influences in Indian populations. Given the close association between MASLD and type 2 diabetes, region-specific prevention, early risk assessment, and integrated metabolic care strategies are increasingly important.
No takes yet. Share an insight, caveat, or question.
Harini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: